Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$108,333.00

Modeling Duchenne dilated cardiomyopathy using patient iPSC-derived cardiomyocytes

FY 2014-15

Summary
Duchenne muscular dystrophy is an X-chromosome-linked genetic disease that is caused by a mutation in the dystrophin gene and affects 1 in every 3500 boys. Duchenne patients suffer progressive muscle wasting and eventual cardiorespiratory failure that results in an early death in the second or third decade of life. Available mouse models do not recapitulate the cardiac phenotype seen in patients. Using a new mouse model, dystrophin-deficient and humanized telomere length, we have identified and characterized a new pathogenic pathway that drives the development of cardiomyopathy. Thus there is a need to validate our findings in the human setting. To address this need, I propose to use induced pluripotent stem cell technology to establish Duchenne patient cardiomyocyte cell lines to study the underlying pathogenesis. These cell lines will enable identification of previously unrecognized signaling pathways implicated in Duchenne cardiomyopathy. I will first characterize how oxidative stress causes telomere shortening. Based on our preliminary data, we postulate that when telomeres are shortened to a critical length, the DNA damage response is activated. This response leads to suppression of mitochondrial biogenesis and function, which are hallmarks of cardiomyopathy. I will then test this hypothesis by performing rescue experiments, entailing treatment of the patient-derived cardiomyocytes with anti-oxidants in combination with telomere extending treatments. Characterization of the proposed pathway in the patient-derived cell lines will constitute a major resource that will be made available to the entire scientific community. These experiments will provide unprecedented insights into Duchenne dilated cardiomyopathy.
Program
CIHR Fellowship
Location
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
318618
Name
Chang Alex C
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Modeling Duchenne dilated cardiomyopathy using patient iPSC-derived cardiomyocytes
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$108,333
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cardiomyopathies; Duchenne Muscular Dystrophy; Dystrophin; Ips; Mitochondria; Telomeres
Abstract
Duchenne muscular dystrophy is an X-chromosome-linked genetic disease that is caused by a mutation in the dystrophin gene and affects 1 in every 3500 boys. Duchenne patients suffer progressive muscle wasting and eventual cardiorespiratory failure that results in an early death in the second or third decade of life. Available mouse models do not recapitulate the cardiac phenotype seen in patients. Using a new mouse model, dystrophin-deficient and humanized telomere length, we have identified and characterized a new pathogenic pathway that drives the development of cardiomyopathy. Thus there is a need to validate our findings in the human setting. To address this need, I propose to use induced pluripotent stem cell technology to establish Duchenne patient cardiomyocyte cell lines to study the underlying pathogenesis. These cell lines will enable identification of previously unrecognized signaling pathways implicated in Duchenne cardiomyopathy. I will first characterize how oxidative stress causes telomere shortening. Based on our preliminary data, we postulate that when telomeres are shortened to a critical length, the DNA damage response is activated. This response leads to suppression of mitochondrial biogenesis and function, which are hallmarks of cardiomyopathy. I will then test this hypothesis by performing rescue experiments, entailing treatment of the patient-derived cardiomyocytes with anti-oxidants in combination with telomere extending treatments. Characterization of the proposed pathway in the patient-derived cell lines will constitute a major resource that will be made available to the entire scientific community. These experiments will provide unprecedented insights into Duchenne dilated cardiomyopathy.
Competitiondate
201411
Approvedterm2
2 yrs 2 mths
Pinamesdelim
Chang, Alex C
Approvedterm
2 ans 2 mois
Cihrcontribution2
~ $108,333~ $0~
Direct Payment - $108,333 Grant (2014-15) | Canada Spends